!

COVID-19 Response

Access our COVID-19 Response homepage, with more information and resources during the COVID-19 pandemic, including what to do if you’re experiencing symptoms.

Research

Circulating Tumor Cells Core Facility

Master
Content

The Circulating Tumor Cells Core is devoted to the biology and enumeration of circulating tumor cells in metastatic cancers.

Media Component
Dario Marchetti, Ph.D., Director, CTC Core
Content

Circulating tumor cells are the ‘seeds' of cancer metastasis. There are millions of these cells at any one time in the blood circulation due to their shedding from the tumor primary site and ability to travel to other parts of the body, causing metastasis and ultimately death.

Heading

Why Is Circulating Tumor Cells Testing Important?

Media Component
Equipment in the CTC Core Facility.
Content

It has been proven that CTC enumeration represents an independent prognostic indicator, and correlates with the survival and potential for relapse in patients with breast, prostate and colorectal cancer. The CTC test, which is distributed by Veridex LLC (a Johnson & Johnson Company), is able to identify, visualize, and count CTC in a small (7.5 ml) blood sample to predict disease progression and survival. Through the ability to locate as low as one CTC among 40 billion cells in the blood sample – an achievement no other diagnostic approach has been able to accomplish – the CTC test can assist oncologists to make timely, informed decisions about patient care. Further, it is the only diagnostic platform which has been approved by the U.S. Federal Drug Administration as unique resource critical for patient management in metastatic cancers of the breast, prostate, and colon, and their monitoring. In these cancer types, it has been proven that CTC act as independent prognostic indicator of patient free and overall survival (see figures below).

Back to topback-to-top